Windtree Therapeutics, a Nasdaq-listed biotech firm, announced its intention to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, to bolster its balance sheet. Following BNB's new all-time high, the company plans to raise $520 million to fund the acquisition, building on its earlier commitment to buy $200 million worth. Windtree will secure the funds through a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp. Partnering with Kraken for asset custody, Windtree's CEO stated that acquiring additional BNB is crucial for their strategic approach. Despite a recent drop in stock price, the company experienced a significant increase of 162% over the past month. This move is part of a growing trend where public companies begin acquiring digital assets, following strategies initiated by other entities like Strategy, which heavily invests in Bitcoin.

Source šŸ”—